Target Price | $4.34 |
Price | $2.48 |
Potential |
74.80%
register free of charge
|
Number of Estimates | 4 |
4 Analysts have issued a price target Oncocyte Corporation 2026 .
The average Oncocyte Corporation target price is $4.34.
This is
74.80%
register free of charge
$8.40
238.71%
register free of charge
$4.04
62.90%
register free of charge
|
|
A rating was issued by 8 analysts: 5 Analysts recommend Oncocyte Corporation to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Oncocyte Corporation stock has an average upside potential 2026 of
74.80%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 1.88 | 0.13 |
25.33% | 93.19% | |
EBITDA Margin | -934.57% | -4,733.73% |
8.01% | 406.51% | |
Net Margin | -3,240.96% | -5,336.41% |
69.27% | 64.66% |
5 Analysts have issued a sales forecast Oncocyte Corporation 2025 . The average Oncocyte Corporation sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Oncocyte Corporation EBITDA forecast 2025. The average Oncocyte Corporation EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2024 | -934.57% | 8.01% |
---|---|---|
2025 |
-4,733.73%
406.51%
Unlock
|
5 Oncocyte Corporation Analysts have issued a net profit forecast 2025. The average Oncocyte Corporation net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -4.66 | -0.24 |
24.27% | 94.85% | |
P/E | negative |
5 Analysts have issued a Oncocyte Corporation forecast for earnings per share. The average Oncocyte Corporation EPS is
This results in the following potential growth metrics and future valuations:
Oncocyte Corporation...
Analyst | Rating | Action | Date |
---|---|---|---|
Lake Street |
Locked
➜
Locked
|
Locked | May 21 2025 |
Needham |
Locked
➜
Locked
|
Locked | May 13 2025 |
Needham |
Locked
➜
Locked
|
Locked | Apr 08 2025 |
Lake Street |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
Stephens & Co. |
Locked
➜
Locked
|
Locked | Mar 26 2025 |
Needham |
Locked
➜
Locked
|
Locked | Mar 25 2025 |
Stephens & Co. |
Locked
➜
Locked
|
Locked | Mar 25 2025 |
Analyst Rating | Date |
---|---|
Locked
Lake Street:
Locked
➜
Locked
|
May 21 2025 |
Locked
Needham:
Locked
➜
Locked
|
May 13 2025 |
Locked
Needham:
Locked
➜
Locked
|
Apr 08 2025 |
Locked
Lake Street:
Locked
➜
Locked
|
Mar 28 2025 |
Locked
Stephens & Co.:
Locked
➜
Locked
|
Mar 26 2025 |
Locked
Needham:
Locked
➜
Locked
|
Mar 25 2025 |
Locked
Stephens & Co.:
Locked
➜
Locked
|
Mar 25 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.